SS&C Technologies Equity Method Investments decreased by 4.2% to $294.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 10.9%, from $330.70M to $294.70M. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows an upward trend with a 6.4% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $219.80M | $219.70M | $306.10M | $308.60M | $308.20M | $236.20M | $266.90M | $257.70M | $265.40M | $286.30M | $345.20M | $346.70M | $337.10M | $327.70M | $328.40M | $330.70M | $344.60M | $333.60M | $307.70M | $294.70M |
| QoQ Change | — | -0.0% | +39.3% | +0.8% | -0.1% | -23.4% | +13.0% | -3.4% | +3.0% | +7.9% | +20.6% | +0.4% | -2.8% | -2.8% | +0.2% | +0.7% | +4.2% | -3.2% | -7.8% | -4.2% |
| YoY Change | — | — | — | — | +40.2% | +7.5% | -12.8% | -16.5% | -13.9% | +21.2% | +29.3% | +34.5% | +27.0% | +14.5% | -4.9% | -4.6% | +2.2% | +1.8% | -6.3% | -10.9% |